Company intelligence / Profile preview

Captozyme

Gainesville, Florida, United Statesprnewswire.com ↗

Ownership: Private
Employees: ~5
Development stage: Phase 1

Overview

Captozyme developed enzyme-based therapeutics and food ingredients targeting oxalate metabolism, with its lead program focused on oral enzyme therapy for hyperoxaluria. Clinical data from a successor company’s candidate showed a 29% mean reduction in urinary oxalate excretion in healthy volunteers on a high oxalate diet, meeting all pre-determined endpoints with no serious adverse events.

Therapeutic areas: Nephrology
Modalities: Enzyme replacement therapyLive biotherapeutic product therapy
Industry: Biotech

Partnerships

Sid Martin Biotechnology Institute at the University of Florida incubator support; no major pharma partnerships disclosed pre-acquisition

Beyond the preview

Go deeper on Captozyme.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Captozyme.

Explore the full profile